FDMT: 4D Molecular Therapeutics, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

SummaryFactSheetFinancial
Price
$9.42
Loss Chance
54.1%
2.35JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Biotechnology
76 / 278
Health Care
310 / 713
United States
?
2,546 / 4,223
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Aurinia Pharmaceuticals
NASDAQ:AUPH
5.68
$16.14
36.42%
Aurinia Pharmaceuticals
NASDAQ:AUPH
5.68
$16.14
36.42%
Catalyst Pharmaceuticals
NASDAQ:CPRX
6.36
$31.40
42.59%
Exelixis
NASDAQ:EXEL
6.93
$52.44
30.64%
Fabien Corp.
NASDAQ:FBIO
1.90
$0.13
100.00%
Jitta Factors
Growth Opportunity (54)
Recent Business Performance (72)
Financial Strength (40)
Return to Shareholders (0)
Competitive Advantage (40)
Jitta Signs
SG&A to SalesDecreasing
Cash Conversion CycleLess than 30 days
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
Recent Business PerformanceEarning decline 39.05% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.35
100.00%
2.21
133.46%
3.05
146.31%
Biotechnology
5.68
36.42%
5.68
36.42%
6.36
42.59%
COMPANY DESCRIPTION
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
www.4dmoleculartherapeutics.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.